Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tigris Pharmaceuticals has executed a cooperative research and development agreement with the National Cancer Institute to collaborate on clinical and preclinical development of AFP-464, an aminoflavone currently in Phase I development.
Subscribe to our email newsletter
This is part of a four-year cooperative research and development agreement (CRADA) encompassing multiple Phase I and Phase II clinical studies with correlating translational research of AFP-464 in a variety of tumor types. The goal of this research collaboration is to work together for the successful development of AFP-464 as a safe and effective novel pharmaceutical compound for the treatment of cancer.
Under this CRADA, two Phase I studies with AFP-464 are currently enrolling in the US, sponsored by the National Cancer Institute (NCI), at the Mayo Clinic, Wayne State University, and the University of Maryland. These studies are evaluating AFP-464 in patients with advanced solid tumors. Tigris has also initiated a Phase I program at leading cancer research centers in Belgium and France; this work is not included in the CRADA research. The AFP-464 program is anticipated to move to Phase II development in 2009.
Edmundo Muniz, CEO of Tigris, said: “This CRADA further solidifies the successful partnership to date between Tigris and the NCI.”